These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 34628521

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ, Conduit C, Davis ID, Effeney RM, Williams S, Martin JM, Hofman MS, Hruby G, Eapen R, Gianacas C, Papa N, Lourenço RA, Dhillon HM, Allen R, Fontela A, Kaur B, Emmett L, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa.
    Schmidt-Hegemann NS, Zamboglou C, Thamm R, Eze C, Kirste S, Spohn S, Li M, Stief C, Bolenz C, Schultze-Seemann W, Bartenstein P, Prasad V, Ganswindt U, Grosu AL, Belka C, Mayer B, Wiegel T.
    Front Oncol; 2021 Feb; 11():723536. PubMed ID: 34660290
    [Abstract] [Full Text] [Related]

  • 49. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.
    Rischke HC, Eiberger AK, Volegova-Neher N, Henne K, Krauss T, Grosu AL, Jilg CA.
    Adv Med Sci; 2016 Sep; 61(2):212-218. PubMed ID: 26895459
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy.
    Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P.
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2804-2815. PubMed ID: 32314028
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL, Koh TL, Lim Joon D, Chao M, Farrugia B, Lau E, Khoo V, Lawrentschuk N, Bolton D, Foroudi F.
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    Staal FHE, Janssen J, Brouwer CL, Langendijk JA, Ng Wei Siang K, Schuit E, de Jong IJ, Verzijlbergen JF, Smeenk RJ, Aluwini S.
    BMC Cancer; 2022 Apr 15; 22(1):416. PubMed ID: 35428210
    [Abstract] [Full Text] [Related]

  • 58. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 15; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 59. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.
    Ilhan H, Kroenke M, Wurzer A, Unterrainer M, Heck M, Belka C, Knorr K, Langbein T, Rauscher I, Schmidt-Hegemann NS, Schiller K, Bartenstein P, Wester HJ, Eiber M.
    J Nucl Med; 2022 Aug 15; 63(8):1208-1214. PubMed ID: 35273094
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.